The ACT-AD Coalition announces its Eighth Annual FDA/Alzheimer’s Disease Allies Meeting, taking place on Wednesday, September 16, 2015, from 10:00 a.m. to 4 p.m. at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Md. This year’s theme is “Assessing the Scientific Foundation for Alzheimer’s Disease Therapeutic Development.”
On July 13, 2015, the U.S. Food and Drug Administration released a report on targeted drug therapy. This report highlighted the lack of success to date in bringing transformative therapies to market for Alzheimer’s disease as well as the factors behind the robust pipelines of treatments that exist today for HIV/AIDS and cancer. FDA’s report emphasized that basic information about the causes of Alzheimer’s disease and pathways to slow its progression is lacking.
This meeting will take participants back to basics, examining lessons from pioneering studies that incorporated Alzheimer’s disease biomarkers and surrogate endpoints. Participants will also explore how genetics and processes like neuroprotection, immunity, metabolism, and inflammation are changing the conceptualization of Alzheimer’s disease. The program will conclude with a candid exchange on practical considerations aimed at improving the prospects for Alzheimer’s disease treatment and prevention trials such as target validation, disease models, endpoint selection, and effect size.
The meeting is scheduled to have the following presentations. You can also access the agenda here:
What Alzheimer’s disease clinical trials have revealed
Rachelle Doody, M.D., Ph.D., Baylor College of Medicine
Changing conceptualization of Alzheimer’s disease
George Perry, Ph.D., The University of Texas San Antonio
What we are learning about Alzheimer’s disease genetics
Bryan Traynor, M.D., Ph.D., MMSc, MRCPI, National Institute on Aging
Scientific and regulatory considerations for advancing pre-clinical
Alzheimer’s disease therapeutic development